A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer
Open Access
- 13 March 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1140993
Abstract
Introduction: Female breast cancer is the most common malignancy worldwide, with a high disease burden. The degradome is the most abundant class of cellular enzymes that play an essential role in regulating cellular activity. Dysregulation of the degradome may disrupt cellular homeostasis and trigger carcinogenesis. Thus we attempted to understand the prognostic role of degradome in breast cancer by means of establishing a prognostic signature based on degradome-related genes (DRGs) and assessed its clinical utility in multiple dimensions.Methods: A total of 625 DRGs were obtained for analysis. Transcriptome data and clinical information of patients with breast cancer from TCGA-BRCA, METABRIC and GSE96058 were collected. NetworkAnalyst and cBioPortal were also utilized for analysis. LASSO regression analysis was employed to construct the degradome signature. Investigations of the degradome signature concerning clinical association, functional characterization, mutation landscape, immune infiltration, immune checkpoint expression and drug priority were orchestrated. Cell phenotype assays including colony formation, CCK8, transwell and wound healing were conducted in MCF-7 and MDA-MB-435S breast cancer cell lines, respectively.Results: A 10-gene signature was developed and verified as an independent prognostic predictor combined with other clinicopathological parameters in breast cancer. The prognostic nomogram based on risk score (calculated based on the degradome signature) showed favourable capability in survival prediction and advantage in clinical benefit. High risk scores were associated with a higher degree of clinicopathological events (T4 stage and HER2-positive) and mutation frequency. Regulation of toll-like receptors and several cell cycle promoting activities were upregulated in the high-risk group. PIK3CA and TP53 mutations were dominant in the low- and high-risk groups, respectively. A significantly positive correlation was observed between the risk score and tumor mutation burden. The infiltration levels of immune cells and the expressions of immune checkpoints were significantly influenced by the risk score. Additionally, the degradome signature adequately predicted the survival of patients undergoing endocrinotherapy or radiotherapy. Patients in the low-risk group may achieve complete response after the first round of chemotherapy with cyclophosphamide and docetaxel, whereas patients in the high-risk group may benefit from 5-flfluorouracil. Several regulators of the PI3K/AKT/mTOR signaling pathway and the CDK family/PARP family were identified as potential molecular targets in the low- and high-risk groups, respectively. In vitro experiments further revealed that the knockdown of ABHD12 and USP41 significantly inhibit the proliferation, invasion and migration of breast cancer cells.Conclusion: Multidimensional evaluation verified the clinical utility of the degradome signature in predicting prognosis, risk stratification and guiding treatment for patients with breast cancer.Keywords
This publication has 55 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and MetastasisScience Translational Medicine, 2012
- CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancerBreast Cancer Research and Treatment, 2010
- Endogenous ligands of TLR2 and TLR4: agonists or assistants?Journal of Leukocyte Biology, 2010
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerNew England Journal of Medicine, 2005
- Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProceedings of the National Academy of Sciences, 2005
- Human and mouse proteases: a comparative genomic approachNature Reviews Genetics, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- Protease degradomics: A new challenge for proteomicsNature Reviews Molecular Cell Biology, 2002